Đang chuẩn bị liên kết để tải về tài liệu:
Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

To investigate the maximum tolerated dose (MTD) of apatinib delivered during and after intensitymodulated radiotherapy (IMRT) for unresectable hepatocellular carcinoma (HCC). |

TÀI LIỆU LIÊN QUAN

Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study)

Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: A dose-finding phase 1 trial

Optimal biological dose: A systematic review in cancer phase I clinical trials

Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: A phase 1 dose-escalation trial

The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study: A phase 1 dosage escalation study

Assessment of various continual reassessment method models for doseescalation phase 1 oncology clinical trials: Using real clinical data and simulation studies

Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): Study protocol for a randomized phase III trial

Rationale and design of LUX-Head & Neck 1: A randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers

A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.